Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026

The chronic obstructive pulmonary disease (copd) treatment market size has grown strongly in recent years. It will grow from $21.73 billion in 2025 to $22.9 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to high smoking prevalence, aging population growth, increased air pollution levels, rising occupational dust exposure, improved copd disease awareness.

The chronic obstructive pulmonary disease (copd) treatment market size is expected to see strong growth in the next few years. It will grow to $29.13 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing adoption of combination therapies, expansion of homecare treatment models, increasing healthcare expenditure, rising copd diagnosis rates, innovation in inhalation drug delivery. Major trends in the forecast period include rising adoption of triple combination inhaler therapies, increasing shift toward home-based copd management, growing focus on early diagnosis and disease screening, expansion of generic and cost-effective copd drugs, higher use of non-pharmacological pulmonary rehabilitation.

The rising prevalence of smoking is anticipated to support the expansion of the chronic obstructive pulmonary disease (COPD) treatment market in the coming years. Smoking involves inhaling smoke, most commonly from the burning of substances such as tobacco, through the mouth. COPD treatment is commonly recommended for individuals with a history of smoking as it helps improve breathing, enhance quality of life, reduce disease exacerbations, increase exercise capacity, extend life expectancy, and support better mental health outcomes. For example, in July 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, tobacco use is responsible for more than 8 million deaths each year, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the growing prevalence of smoking is driving the growth of the chronic obstructive pulmonary disease (COPD) treatment market.

Key companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are emphasizing the development of innovative products, such as Vilfuro-G, to enhance revenue generation. Vilfuro-G is recognized as the world’s first fixed-dose triple combination medication specifically designed for the effective treatment of COPD. For instance, in November 2023, Lupin Limited, an India-based pharmaceutical company, launched Vilfuro-G. The medication is available in a single fixed strength and is recommended for once-daily administration. The launch of Vilfuro-G is expected to significantly improve the quality of life for COPD patients while expanding Lupin’s respiratory product portfolio, reflecting the company’s commitment to offering advanced treatment options for patients and healthcare professionals. Vilfuro-G is the only fixed-dose combination formulated to integrate glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term management and treatment of moderate to severe COPD.

In March 2023, UC Davis Health, a US-based health system, partnered with Propeller Health. This collaboration highlights a commitment to leveraging digital health technologies to improve clinical outcomes and enhance care for individuals living with chronic conditions such as asthma and COPD. The partnership utilizes Propeller Health’s remote monitoring program, which includes sensors, a mobile application, a web-based interface, and personalized support, to deliver tailored care for high-risk patients affected by these respiratory diseases.

Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic obstructive pulmonary disease (copd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the copd treatment market by increasing costs for imported active pharmaceutical ingredients, inhaler devices, and medical-grade components used in respiratory drugs. These impacts are most visible in combination therapies, bronchodilators, and inhalation-based treatments, with asia-pacific and europe facing notable supply chain pressures due to manufacturing dependence. Hospitals and clinics experience higher procurement costs, while homecare settings see delayed device availability. On the positive side, tariffs are encouraging local manufacturing, generic drug production, and regional sourcing strategies, supporting long-term supply resilience.

The chronic obstructive pulmonary disease (copd) treatment market research report is one of a series of new reports that provides chronic obstructive pulmonary disease (copd) treatment market statistics, including chronic obstructive pulmonary disease (copd) treatment industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (copd) treatment market share, detailed chronic obstructive pulmonary disease (copd) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (copd) treatment industry. This chronic obstructive pulmonary disease (copd) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic obstructive pulmonary disease (COPD) treatment refers to the medical care provided to patients to help control symptoms, slow disease progression, and enhance the overall quality of life for individuals living with COPD. COPD is a progressive respiratory condition marked by airflow limitation, persistent inflammation, and damage to lung tissue.

The primary types of drugs used in chronic obstructive pulmonary disease (COPD) treatment include combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. Combination therapy involves a treatment approach in which more than one therapy is administered to a patient. It includes treatment regimens that require patients to take multiple tablets, each containing a specific medication. This approach is used to treat conditions such as chronic bronchitis and emphysema and is predominantly utilized in hospitals, clinics, and homecare settings.

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.